Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: J Cardiovasc Comput Tomogr. 2016 Jul 12;10(6):500–506. doi: 10.1016/j.jcct.2016.07.009

Table 1.

Baseline characteristics and number of events per LVA-BSA quartiles of the MESA population 2000–2002.

Variable LVA-BSA 1st
quartile
LVA-BSA 2nd
quartile
LVA-BSA 3rd
quartile
LVA-BSA 4th
quartile
p
Population size 1697 1693 1697 1694
Age (years) 62.3±10.1 62.2±10.1 61.5±10.3 62.5±10.4 0.03
Men (%) 629 (37%) 732 (43%) 821 (49%) 1009 (60%) <0.001
Race (%) <0.001
  White 878 (52%) 700 (42%) 583 (35%) 441 (26%)
  Hispanic 268 (16%) 326 (19%) 411 (24%) 489 (29%)
  African-American 415 (24%) 463 (27%) 479 (28%) 507 (30%)
  Chinese 130 (8%) 200 (12%) 214 (13%) 257 (15%)
Smoking (%) <0.001
    Never 791 (47%) 852 (50%) 866 (51%) 893 (53%)
    Former 661 (39%) 641 (38%) 620 (37%) 555 (33%)
Current 239 (14%) 196 (12%) 201 (12%) 246 (14%)
Family history of
CHD (%)
735 (46%) 677 (43%) 682 (43%) 617 (39%) 0.001
Diabetes (%) 132 (8%) 145 (9%) 172 (10%) 209 (12%) <0.001
Hypertension (%) 615 (36%) 708 (42%) 779 (46%) 929 (55%) <0.001
Systolic BP (mmHg) 122±19 125±21 126±21 132±28 <0.001
Diastolic BP
(mmHg)
70±10 71±10 72±10 74±10 <0.001
BMI (kg/m2) 28.8±6.2 28.6±5.6 28.2±5.1 27.7±4.7 <0.001
LDL (mg/dL) 117±32 118±32 117±31 116±31 0.5
HDL (mg/dL) 52±15 51±15 51±15 50±14 <0.001
Triglycerides
(mg/dL)
131±78 133±79 134±108 129±87 0.51
Anti-hypertensive
therapy (%)
547 (32%) 584 (35%) 645 (38%0 735 (43%) <0.001
Lipid lowering
therapy (%)
315 (19%) 279 (17%) 265 (16%) 234 (14%) 0.002
Coronary Artery
Calcium Score
124±333 130±240 138±435 191±527 <0.001 <0.001
Events
Heart Failure 37 (2.2%) 40 (2.4%) 54 (3.2%) 106 (6.2%)
CHD events 95 (5.6%) 100 (5.9%) 102 (6.0%) 152 (8.9%)
Cardiovascular
events
131 (7.7%) 143 (8.4%) 148 (8.7%) 217 (12.8%

Values are mean ± SD, median (interquartile range), or n (%).

BMI= body mass index, BP= blood pressure, CHD: coronary heart disease, HDL= high-density lipoprotein, LDL= low-density lipoprotein.